IRON vs. PRAX, ALXO, LBPH, EOLS, ARCT, TNGX, DNTH, PRTC, ZNTL, and AUPH
Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Praxis Precision Medicines (PRAX), ALX Oncology (ALXO), Longboard Pharmaceuticals (LBPH), Evolus (EOLS), Arcturus Therapeutics (ARCT), Tango Therapeutics (TNGX), Dianthus Therapeutics (DNTH), PureTech Health (PRTC), Zentalis Pharmaceuticals (ZNTL), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Disc Medicine (NASDAQ:IRON) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Disc Medicine has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -5,711.85%. Disc Medicine's return on equity of -22.81% beat Praxis Precision Medicines' return on equity.
Disc Medicine currently has a consensus target price of $57.71, suggesting a potential upside of 79.35%. Praxis Precision Medicines has a consensus target price of $105.80, suggesting a potential upside of 133.09%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Disc Medicine.
In the previous week, Praxis Precision Medicines had 15 more articles in the media than Disc Medicine. MarketBeat recorded 31 mentions for Praxis Precision Medicines and 16 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.62 beat Praxis Precision Medicines' score of 0.21 indicating that Disc Medicine is being referred to more favorably in the media.
83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Disc Medicine and Praxis Precision Medicines both received 26 outperform votes by MarketBeat users. However, 74.29% of users gave Disc Medicine an outperform vote while only 63.41% of users gave Praxis Precision Medicines an outperform vote.
Disc Medicine has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.
Disc Medicine has higher earnings, but lower revenue than Praxis Precision Medicines. Disc Medicine is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Disc Medicine beats Praxis Precision Medicines on 11 of the 16 factors compared between the two stocks.
Get Disc Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Disc Medicine Competitors List
Related Companies and Tools
